Pawel Chrom1, Rafal Stec2, Aleksandra Semeniuk-Wojtas2, Lubomir Bodnar2, Nathaniel J Spencer3, Cezary Szczylik2. 1. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. Electronic address: pawel.chrom@gmail.com. 2. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. 3. Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Abstract
BACKGROUND: The present study investigated the various features that might influence the overall survival (OS) of patients with metastatic renal cell carcinoma (RCC) treated with first-line tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: A retrospective analysis was performed of consecutive patients with metastatic RCC, in whom treatment with a first-line TKI was initiated from January 2010 to December 2014, at the Department of Oncology, Military Institute of Medicine (Warsaw, Poland). Cox proportional hazards regression was used to construct a prognostic model that included independent factors for OS. We validated the model using 2 bootstrap procedures and calculation of the bias-corrected concordance index. RESULTS: Of the 266 patients included in the study, 201, 45, and 20 received sunitinib, pazopanib, and sorafenib, respectively. The median OS for the whole cohort was 24.8 months (95% confidence interval, 20.2-29.4 months). Six factors were independently associated with poor survival: Eastern Cooperative Oncology Group performance status > 0 (P < .0001), Fuhrman grade 3 to 4 (P < .0001), hemoglobin less than the lower limit of normal (P < .0001), lactate dehydrogenase greater than the upper limit of normal (P = .0011), neutrophil-to-lymphocyte ratio ≥ 4 (P < .0001), and > 2 metastatic sites (P = .0012). The bias-corrected concordance index was 0.751. CONCLUSION: Fuhrman grade and neutrophil-to-lymphocyte ratio are potential factors that affect the survival of patients with metastatic RCC treated with first-line TKIs. The presented prognostic model demonstrated satisfactory performance but requires external validation with a larger data set.
BACKGROUND: The present study investigated the various features that might influence the overall survival (OS) of patients with metastatic renal cell carcinoma (RCC) treated with first-line tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: A retrospective analysis was performed of consecutive patients with metastatic RCC, in whom treatment with a first-line TKI was initiated from January 2010 to December 2014, at the Department of Oncology, Military Institute of Medicine (Warsaw, Poland). Cox proportional hazards regression was used to construct a prognostic model that included independent factors for OS. We validated the model using 2 bootstrap procedures and calculation of the bias-corrected concordance index. RESULTS: Of the 266 patients included in the study, 201, 45, and 20 received sunitinib, pazopanib, and sorafenib, respectively. The median OS for the whole cohort was 24.8 months (95% confidence interval, 20.2-29.4 months). Six factors were independently associated with poor survival: Eastern Cooperative Oncology Group performance status > 0 (P < .0001), Fuhrman grade 3 to 4 (P < .0001), hemoglobin less than the lower limit of normal (P < .0001), lactate dehydrogenase greater than the upper limit of normal (P = .0011), neutrophil-to-lymphocyte ratio ≥ 4 (P < .0001), and > 2 metastatic sites (P = .0012). The bias-corrected concordance index was 0.751. CONCLUSION: Fuhrman grade and neutrophil-to-lymphocyte ratio are potential factors that affect the survival of patients with metastatic RCC treated with first-line TKIs. The presented prognostic model demonstrated satisfactory performance but requires external validation with a larger data set.
Authors: Alicia-Marie Conway; Zena Salih; George Papaxoinis; Kimberly Fletcher; Jamie Weaver; Ana Patrao; Robert Noble; Sofia Stamatopoulou; Vikki Owen-Holt; Wasat Mansoor Journal: Med Oncol Date: 2017-05-12 Impact factor: 3.064
Authors: Edmund K Bartlett; Jessica R Flynn; Katherine S Panageas; Richard A Ferraro; Jessica M Sta Cruz; Michael A Postow; Daniel G Coit; Charlotte E Ariyan Journal: Cancer Date: 2019-10-04 Impact factor: 6.860
Authors: Oktay Halit Aktepe; Gürkan Güner; Deniz Can Güven; Taha Koray Şahin; Fadime Sinem Ardıç; Deniz Yüce; Şuayib Yalçın; Mustafa Erman Journal: Turk J Med Sci Date: 2021-04-30 Impact factor: 0.973
Authors: Tae Ju Park; Yang Hyun Cho; Ho Seok Chung; Eu Chang Hwang; Sung-Hoon Jung; Jun Eul Hwang; Woo Kyun Bae; Jin Woong Kim; Suk Hee Heo; Young Hoe Hur; Seung Il Jung; Dong Deuk Kwon Journal: Springerplus Date: 2016-10-28
Authors: Jang Hee Han; Seung Hwan Lee; Won Sik Ham; Woong Kyu Han; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Young Eun Yoon Journal: Oncotarget Date: 2017-08-12